household person unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
remain ew pg improv fundament outlook
larg price valuat post outsiz stock
move ep although pg still trade price-to-earnings
somewhat cautiou expect head print pg stock rose larg
vs driven strong inflect organ sale
growth bp market expect along better
expect ep guidanc pg held fy y-o-i ep growth rang despit
increment bp fx headwind gross margin perform
bp y-o-i neg fx/commod unfavor mix remain weak
like linger importantli result mark real top-line
progress catalyz greater confid strategi tweak put place last
sever year acceler pg organ sale trajectori back rang
level pg achiev sinc potenti beyond net
dont disagre magnitud stock reaction particularli given pg
rel compress vs peer last month howev remain ew
given view improv growth outlook discount
stock pg ep seem reason compani
believ grow organ sale rang go forward base
case assum pg multipl expand ep slightli ko
current offer organ sale rang said pg price-to-earnings
discount vs hpc peer cl/chd/clx/kmb look somewhat larg us
indic room rel out-performance see key emerg
high end fy organ sale guidanc look achiev
organ sale growth unround pg best result
sinc believ higher end pg fy organ sale
guidanc look achiev deliveri organ sale growth
would impli bp slowdown averag growth balanc
year hold averag growth constant point
y-o-i organ sale growth balanc year use
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
appropri average last two quarter combin given
round quarter mind unsustain groom
result impli boy growth in-lin forecast term
forward growth pg note us rebound drove acceler
organ sale strong us perform month
septemb momentum continu octob far
improv pg market share perform pg make progress improv
market share perform bp sale weight averag
basi first posit result far back model track back
well bp averag declin prior twelv month
although privat label momentum us continu bp y-o-
pg market share rebound augment modestli improv
categori growth particularli us
neg quarter weak gross margin perform although
market anticip miss front gm
bp y-o-i bp consensu like bp
assum account chang fulli reflect consensu
unfavor commod bp fx bp geograph mix
bp off-set cost save bp weak
linger line item build suggest gross margin expans
return product price contribut build
commodity/freight headwind moder
rais eps/pric target ep beat tweak
ep estim larg driven
increas top-line outlook upsid pt move
base ep reflect robust top-line
outlook higher stapl multipl given defens market orient
number pg core ep on-consensu
estim led top-line upsid robust organ sale growth solid
sg leverag offset gm weak drove profit beat vs
consensu organ sale growth pg best result sinc
roughli unround came well consensu
well market expect rang led strong acceler
us roughli in-lin corpor result two-year averag growth
also acceler vs price improv sequenti flat
quarter vs y-o-i declin report top-line beat
partial off-set weaker expect gross margin bp
consensu like bp assum partial adjust consensu
account chang gm bp y-o-i unfavor commod
bp fx bp geograph mix bp off-set cost
save bp mitig gm downsid sg sale came bp
consensu driven product save bp sale leverag
bp net bp oper margin miss
ep guidanc reiter despit greater fx headwind pg reiter
organ sale growth guidanc all-in sale growth
flat prior includ fx headwind net
effect acquisit divestitur modest posit impact
all-in sale growth prior fx/divestitur compani reiter
core ep growth base impli despit higher
fx headwind mean underli guidanc rais pg guidanc midpoint
consensu head quarter pg
guidanc includ billion billion prior headwind foreign
exchang higher commod cost pg reiter adjust free cash flow
product guidanc better expect pay
billion dividend unchang repurchas billion common
exhibit pg weight averag market share perform turn posit
exhibit pg organ sale growth acceler materi
deriv base case scenario
top-line rebound organ sale growth revenu upsid bp
int upsid bp us upsid pg marketing/innov focu drive
market share improv cut forecast drive margin
upsid turn hsd ep growth valuat expand ep
growth pg go forward slightli peer
rang given pg premium portfolio develop market skew limit growth
expect pg om expand bp drive msd ep growth
appli multipl ep toward lower-end pg
us led topline/margin downsid us bear case scenario play
pricing/volum downsid along bp margin downsid
greater reinvest outsid us bp top-line downsid
bp margin downsid drive mute flat lsd ep growth valuat
contract ep
organ sale growth pg best result
sinc led acceler growth
us believ higher end pg
strategi tweak appear
yield top-line payback long-term
skew portfolio limit top-line growth
rate modestli hpc peer
posit chang believ
posit chang put
place pg includ substanti cost-
cut re-focu core shift
decis make local level better tie
compens individu perform
compel pg trade
ep still larg discount hpc peer
particularli pg narrow gap
risk achiev price
market share vacil currenc
exhibit bear bull top-line trend stock driver
valu
sale
sale
sale bp chang
sale
sale bp chang
